These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23970181)

  • 1. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
    Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
    QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
    [No Abstract]   [Full Text] [Related]  

  • 2. Tuberculosis after anti-TNF therapy: a continuous learning process.
    Psichogiou M; Sfikakis PP; Kontos F; Daikos GL
    Scand J Rheumatol; 2012 Oct; 41(5):401-3. PubMed ID: 22803620
    [No Abstract]   [Full Text] [Related]  

  • 3. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
    Winthrop KL
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382
    [No Abstract]   [Full Text] [Related]  

  • 4. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
    Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
    Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.
    Schoffelen T; Kampschreur LM; van Roeden SE; Wever PC; den Broeder AA; Nabuurs-Franssen MH; Sprong T; Joosten LA; van Riel PL; Oosterheert JJ; van Deuren M; Creemers MC
    Ann Rheum Dis; 2014 Jul; 73(7):1436-8. PubMed ID: 24794150
    [No Abstract]   [Full Text] [Related]  

  • 6. Infection and anti-tumor necrosis factor-alpha therapy.
    Zandman-Goddard G
    Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
    [No Abstract]   [Full Text] [Related]  

  • 7. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium chelonae infection associated with adalimumab therapy.
    Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R
    Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777
    [No Abstract]   [Full Text] [Related]  

  • 9. Vasculitis, vitiligo, thyroiditis, and altered hormone levels after anti-tumor necrosis factor therapy.
    Lahita RG; Vernace MA
    J Rheumatol; 2011 Mar; 38(3):579-80. PubMed ID: 21362795
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
    Cisternas M; Gutiérrez M; Jacobelli S
    Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
    Ke WM; Chen LS; Parng IM; Chen WW; On AW
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2012 Oct; 139(10):695-6. PubMed ID: 23122389
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miliary tuberculosis following negative latent tuberculosis infection screening prior to tumor necrosis factor-α antagonists: implications for management?
    Teh BW; Street AC; McBryde ES; Denholm JT
    J Rheumatol; 2012 Jun; 39(6):1297-8. PubMed ID: 22661422
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 17. Mesenteric and splenic cat-scratch disease during etanercept therapy.
    Schiffmann A; Pers YM; Lukas C; Combe B; Morel J
    Rheumatology (Oxford); 2009 Nov; 48(11):1461-2. PubMed ID: 19690129
    [No Abstract]   [Full Text] [Related]  

  • 18. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
    Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
    Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.